Log in

NASDAQ:PCRXPacira Biosciences Stock Price, Forecast & News

$35.69
+2.30 (+6.89 %)
(As of 04/10/2020 05:19 AM ET)
Add
Compare
Today's Range
$33.61
Now: $35.69
$35.76
50-Day Range
$28.40
MA: $37.40
$50.70
52-Week Range
$27.46
Now: $35.69
$51.35
Volume608,400 shs
Average Volume679,378 shs
Market Capitalization$1.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure. It offers EXPAREL, a non-opioid medication administered at the time of surgery to control pain while reducing opioid requirements; and iovera system, a handheld cryoanalgesia device used to deliver controlled doses of cold temperature only to targeted nerves. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was founded in 2006 and is based in Parsippany, New Jersey.
Read More
Pacira Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$421.03 million
Cash Flow$1.89 per share
Book Value$8.51 per share

Profitability

Net Income$-11,020,000.00

Miscellaneous

Employees518
Market Cap$1.50 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive PCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.


Pacira Biosciences (NASDAQ:PCRX) Frequently Asked Questions

How has Pacira Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PCRX shares have increased by 1.4% and is now trading at $35.69. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Pacira Biosciences?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences.

When is Pacira Biosciences' next earnings date?

Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Pacira Biosciences.

How were Pacira Biosciences' earnings last quarter?

Pacira Biosciences Inc (NASDAQ:PCRX) announced its earnings results on Thursday, February, 20th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.21 by $0.35. The firm earned $122.42 million during the quarter, compared to analysts' expectations of $122.04 million. Pacira Biosciences had a negative net margin of 2.62% and a positive return on equity of 10.81%. The business's revenue for the quarter was up 28.7% on a year-over-year basis. During the same period last year, the business posted $0.47 EPS. View Pacira Biosciences' earnings history.

What guidance has Pacira Biosciences issued on next quarter's earnings?

Pacira Biosciences updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $485-500 million, compared to the consensus revenue estimate of $495.91 million.

What price target have analysts set for PCRX?

15 brokers have issued 1-year price targets for Pacira Biosciences' stock. Their forecasts range from $38.00 to $85.00. On average, they expect Pacira Biosciences' stock price to reach $53.67 in the next year. This suggests a possible upside of 50.4% from the stock's current price. View analysts' price targets for Pacira Biosciences.

What are Wall Street analysts saying about Pacira Biosciences stock?

Here are some recent quotes from research analysts about Pacira Biosciences stock:
  • 1. According to Zacks Investment Research, "Pacira changed its name to Pacira BioSciences after acquiring MyoScience in April 2019 following which, it added the latter’s iovera system to its portfolio.. Pacira's top line mainly comprises contribution from its marketed drug Exparel, which continues to maintain momentum. The drug’s label expansion to include administration via nerve block for prolonged regional analgesia is expected to further boost sales in the days ahead. Pacira’s agreement with Nuance for the development and commercialization of Exparel in China is a tailwind. The company's shares have outperformed the industry in the past year. However, Pacira remains heavily dependent on Exparel for growth. Therefore, any regulatory setback for the drug will severely hurt the stock." (3/27/2020)
  • 2. Stifel Nicolaus analysts commented, "We are upgrading shares of PCRX to Hold as we believe the near-term competitive threat from HRTX’s HTX-011 will be less of a factor over the next 12 months and the recent strength in the stock indicates to us that the stock is fairly valued at these levels. While PCRX’s Exparel revenues came in a little shy of 1Q19 consensus, we believe the recent price increase on Exparel, the lack of a competitive entry from HRTX and the favorable reimbursement scheme in the ASC setting should allow PCRX to achieve its 2019 Exparel guidance, in our view. Our revised 2019 Exparel estimates are now at the midpoint of management’s guidance of ~$400-$410 million (vs. consensus of ~$403 million). Additionally, we incorporate PCRX’s recent acquisition, Iovera, into our model and raise our target price to $45 a share." (5/2/2019)

Has Pacira Biosciences been receiving favorable news coverage?

Press coverage about PCRX stock has trended very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Pacira Biosciences earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutPacira Biosciences.

Who are some of Pacira Biosciences' key competitors?

What other stocks do shareholders of Pacira Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Micron Technology (MU), Netflix (NFLX), Alibaba Group (BABA), Bausch Health Companies (BHC) and Exelixis (EXEL).

Who are Pacira Biosciences' key executives?

Pacira Biosciences' management team includes the following people:
  • Mr. David M. Stack, Chairman & CEO (Age 69)
  • Mr. Charles A. Reinhart III, CPA, M.B.A., Chief Financial Officer (Age 58)
  • Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 45)
  • Dr. Richard Scranton M.D., MPH, Chief Medical Officer (Age 52)
  • Mr. Dennis McLoughlin, Chief Commercial Officer (Age 53)

What is Pacira Biosciences' stock symbol?

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira Biosciences' major shareholders?

Pacira Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.09%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings, Richard Scranton and Roy Winston. View institutional ownership trends for Pacira Biosciences.

Which major investors are buying Pacira Biosciences stock?

PCRX stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace, Mark A Kronenfeld, and Roy Winston. View insider buying and selling activity for Pacira Biosciences.

How do I buy shares of Pacira Biosciences?

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pacira Biosciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $35.69.

How big of a company is Pacira Biosciences?

Pacira Biosciences has a market capitalization of $1.50 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe. View additional information about Pacira Biosciences.

What is Pacira Biosciences' official website?

The official website for Pacira Biosciences is http://www.pacira.com/.

How can I contact Pacira Biosciences?

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]

This page was last updated on 4/10/2020 by MarketBeat.com Staff

Featured Article: What is the CAC 40 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel